ARCA biopharma (ARCA biopharma) Change In Working Capital : $0.36 Mil (TTM As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Change In Working Capital?

ARCA biopharma's change in working capital for the quarter that ended in Mar. 2024 was $0.35 Mil.

ARCA biopharma's change in working capital for the fiscal year that ended in Dec. 2023 was $-0.47 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

ARCA biopharma Change In Working Capital Historical Data

The historical data trend for ARCA biopharma's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Change In Working Capital Chart

ARCA biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

0.44

1.88

-0.03

-1.66

-0.47

ARCA biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															-0.48	0.57	-0.43	-0.13	0.35

ARCA biopharma Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.36 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

ARCA biopharma Change In Working Capital Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ARCA biopharma (ARCA biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (NAS:ABIO) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

HQ10:Germany

Address

10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021

Website

http://www.arcabiopharma.com

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Executives

James P Flynn	director	41 HARRIS CT, DANVILLE CA 94526
Funicular Funds, Lp	10 percent owner, other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Funicular Fund, Lp	other: See Footnote 1	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Jacob Ma-weaver	other: See Remarks	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Christopher David Ozeroff	officer: S.V.P., General Counsel	8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021
Robert E Conway	director	C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
C. Jeffrey Dekker	officer: Chief Financial Officer	10170 CHURCH RANCH WAY, WESTMINSTER CO 80021
Thomas A Keuer	officer: Chief Operating Officer	C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021
Brian L. Selby	officer: VP, Finance	11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020
Venrock Healthcare Capital Partners Lp	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Scott D Sandell	10 percent owner
David M Mott	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Forest Baskett	10 percent owner
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202